Literature DB >> 23079397

RNA biomarkers in colorectal cancer.

Stephen A Bustin1, Jamie Murphy.   

Abstract

Colorectal cancer (CRC) develops and progresses through a systematic selection for (epi) genetic alterations that drive the transformation from normal colon epithelium to adenocarcinoma. These changes affect both noncoding RNAs and mRNAs and so define the clinical behaviour of cancer cells within a distinctive host genetic and environmental context. Although earlier diagnosis and more effective treatment modalities have decreased mortality from CRC, prognostic stratification and adjuvant therapy selection after surgery remain dependent on broad descriptive classifications, opportune histological markers of poor prognosis and chemotherapy efficacy data derived from diverse CRC populations. Crucially, there is significant inter- and intra-individual variability in response to, and tolerance of, chemotherapy treatments. These limitations explain the small clinical benefit of new agents studied in contemporary phase III trials. Molecular assays have the potential to address these constraints and there has been intense interest in the identification of clinically relevant molecular biomarkers. These must be easy to obtain and quantify and ideally represent steps in well-understood carcinogenic pathways or host-response mechanisms. Although some biomarkers can provide broad prognostic information based on CRC subtype (e.g. MSI status) or can somewhat predict response to targeted therapies (e.g. KRAS), no RNA-based biomarkers have entered routine clinical practice. This is due, in part, to the genetic heterogeneity of both patients and CRC. In addition, serious underlying issues with regards to study design, poor technical protocols, inadequate quality controls and inappropriate data analysis prevent successful translation of research results. Consequently, the identification of clinically relevant panels of biomarkers will depend not just on further advances in our understanding of CRC biology, but will need to be coupled with appropriate study designs and more suitable, standardised and transparent techniques.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23079397     DOI: 10.1016/j.ymeth.2012.10.003

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  7 in total

Review 1.  Antisense RNA: the new favorite in genetic research.

Authors:  Jian-Zhong Xu; Jun-Lan Zhang; Wei-Guo Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2018 Oct.       Impact factor: 3.066

2.  Extended lymphadenectomy in colon cancer is debatable.

Authors:  Jamie Murphy; Tonia Young-Fadok
Journal:  World J Surg       Date:  2013-08       Impact factor: 3.352

3.  Development and characterization of a colon PDX model that reproduces drug responsiveness and the mutation profiles of its original tumor.

Authors:  Hyang Sook Seol; Hyo Jeong Kang; Hyojeong Kang; Seul-I Lee; Na Eun Kim; Tae Im Kim; Sung Min Chun; Tae Won Kim; Chang Sik Yu; Young-Ah Suh; Shree Ram Singh; Suhwan Chang; Se Jin Jang
Journal:  Cancer Lett       Date:  2013-12-11       Impact factor: 8.679

Review 4.  Evolving notions on immune response in colorectal cancer and their implications for biomarker development.

Authors:  Fabio Grizzi; Gianluca Basso; Elena Monica Borroni; Tommaso Cavalleri; Paolo Bianchi; Sanja Stifter; Maurizio Chiriva-Internati; Alberto Malesci; Luigi Laghi
Journal:  Inflamm Res       Date:  2018-01-10       Impact factor: 4.575

Review 5.  Tailored Systemic Therapy for Colorectal Cancer Liver Metastases.

Authors:  Carolin Czauderna; Kim Luley; Nikolas von Bubnoff; Jens U Marquardt
Journal:  Int J Mol Sci       Date:  2021-10-29       Impact factor: 5.923

Review 6.  MicroRNAs and long non-coding RNAs: prospects in diagnostics and therapy of cancer.

Authors:  Nina Hauptman; Damjan Glavac
Journal:  Radiol Oncol       Date:  2013-10-08       Impact factor: 2.991

7.  Serum availability affects expression of common house-keeping genes in colon adenocarcinoma cell lines: implications for quantitative real-time PCR studies.

Authors:  Malgorzata Krzystek-Korpacka; Katarzyna Hotowy; Elzbieta Czapinska; Magdalena Podkowik; Jacek Bania; Andrzej Gamian; Iwona Bednarz-Misa
Journal:  Cytotechnology       Date:  2016-06-23       Impact factor: 2.058

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.